Commentary
Diagnosis and management of extrahepatic manifestations of NAFLD are crucial for the treatment of these patients. These manifestations include cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy.
The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality.
In their review, K. Wijarnpreecha et al. (Mayo Clinic College of Medicine, Florida, USA) focus on the monitoring and management of the extrahepatic manifestations of NAFLD in order to help clinicians to identify high-risk patients earlier in the disease course and to improve liver disease outcomes.
